Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Q3 Revenues Increase 9 Percent as Company Turns a Profit

NEW YORK, Oct. 28 (GenomeWeb News) - Molecular Devices yesterday reported a 9-percent increase in revenue and has turned a profit for the third quarter of 2005.


Revenues for the quarter ended Sept. 30 totaled $45.2 million, an 8.8percent increase over last year's revenues of $41.5 million during the same quarter.


"In life sciences, we continued to see strong demand for our SpectraMax M5 bench-top reader," Joseph Keegan, Molecular Devices' president and CEO, said in a statement. "In drug discovery, we saw excellent growth in both our high-throughput electrophysiology and FLIPR product lines."


R&D spendning in the quarter remained flat at $6.4 million, the company said.


Molecular Devices posted a $4.6-million profit in the third quarter, compared with a $1.3-million loss year over year.


As of Sept. 30, Molecular Devices had $12.2 million in cash and cash equivalents.


Molecular Devices said it anticipates revenues of $52 million to $54 million in the fourth quarter, an increase of between 9.4 percent and 13.7 percent. The company also said it anticipates revenues of $181 million to $183 million for the full year of 2005.


For the full year 2006, Molecular Devices said it anticipates revenues of $192 million to $202 million.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.